Of the 62% of participants in a CanPath study who had infection-acquired antibodies, 86% had never suspected they had previously had COVID-19. These results from the CanPath SUPPORT-Canada study “Real-world insights on COVID-19 vaccine effectiveness and risk factors for COVID-19 infection” were made public during a hybrid event on May 30th.
The HostSeq platform, established in April 2020, is a national collaboration of population-based studies investigating genetic risk factors for SARS-CoV-2 disease and the health outcomes associated COVID-19.
Despite all donors having vaccine-induced antibodies, the latest CITF-funded seroprevalence report from Canadian Blood Services showed seroprevalence due to infection was 78.3% by mid-March, consistent with the continued presence of circulating Omicron subvariants.
The latest CITF-funded seroprevalence report from Canadian Blood Services showed that seroprevalence due to natural infection was 77.6% at the end of February.
A systematic review published in BMJ Open, drawing on data from the CITF-funded Serotracker initiative led by Dr. Rahul Arora (University of Calgary), highlights that SARS-CoV-2 seroprevalence varied widely across occupations during the first year of the pandemic.
In its latest CITF-funded seroprevalence report, Canadian Blood Services suggest that 77.3% of blood donors had infection-acquired antibodies by mid-February.
Despite all donors having vaccine-related antibodies, seroprevalence data from Canadian Blood Services suggested that 76.2% of donors had infection-acquired antibodies by mid-January 2023.
Canadian Blood Services data suggest that 73.5% of donors had infection-acquired antibodies by the end of 2022. This was slightly higher than the 71% estimated at the end of November.
Canadian Blood Services data suggest 73.3% of donors had infection-acquired antibodies by mid-December 2022 – slightly higher than the 71% Canadian Blood Services estimated at the end of November.
In a letter published in CMAJ, CITF-funded researchers Drs. Sheila O’Brien and Stephen Drews (Canadian Blood Services) argue that blood donor surveillance would make a valuable contribution to public health efforts to monitor emerging pathogens.